Progenics Pharmaceuticals (FRA:PGP) Change In Receivables : €-0.96 Mil (TTM As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Change In Receivables?

Progenics Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2020 was €8.86 Mil. It means Progenics Pharmaceuticals's Accounts Receivable declined by €8.86 Mil from Dec. 2019 to Mar. 2020 .

Progenics Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2019 was €-10.96 Mil. It means Progenics Pharmaceuticals's Accounts Receivable increased by €10.96 Mil from Dec. 2018 to Dec. 2019 .

Progenics Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2020 was €5.60 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Progenics Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2020 was 90.41.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Progenics Pharmaceuticals's liquidation value for the three months ended in Mar. 2020 was €-30.37 Mil.

Progenics Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Progenics Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Change In Receivables Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Change In Receivables

Get a 7-Day Free Trial

-3.14

-1.25

0.75

0.18

-10.96

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Change In Receivables	Get a 7-Day Free Trial															-1.01	-4.98	3.99	-8.82	8.86

Progenics Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.96 Mil.

Progenics Pharmaceuticals (FRA:PGP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Progenics Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2020 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5.602	/	5.654	*	91
=	90.41

2. In Ben Graham's calculation of liquidation value, Progenics Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Progenics Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2020 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	26.726	-	61.297	+	0.75 * 5.602	+	0.5 * 0
=	-30.37

Progenics Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (FRA:PGP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga • 06-16-2023